The use of reverse transcription-PCR for the diagnosis of X-linked chronic granulomatous disease

Chronic granulomatous disease (CGD) is an inherited disorder of the innate immune system characterized by a defective oxidative burst of phagocytes and subsequent impairment of their microbicidal activity. Mutations in one of the NADPH-oxidase components affect gene expression or function of this system, leading to the phenotype of CGD. Defects in gp91-phox lead to X-linked CGD, responsible for approximately 70% of CGD cases. Investigation of the highly heterogeneous genotype of CGD patients includes mutation analysis, Northern blot or Western blot assays according to the particular case. The aim of the present study was to use reverse transcription (RT)-PCR for the analysis of molecular defects responsible for X-linked CGD in eight Brazilian patients and to assess its potential for broader application to molecular screening in CGD. Total RNA was prepared from Epstein B virus-transformed B-lymphocytes and reverse transcribed using random hexamers. The resulting cDNA was PCR-amplified by specific and overlapping pairs of primers designed to amplify three regions of the gp91-phox gene: exons 1-5, 3-9, and 7-13. This strategy detected defective gp91-phox expression in seven patients. The RT-PCR results matched clinical history, biochemical data (nitroblue tetrazolium or superoxide release assay) and available mutation analysis in four cases. In three additional cases, RT-PCR results matched clinical history and biochemical data. In another case, RT-PCR was normal despite a clinical history compatible with CGD and defective respiratory burst. We conclude that this new application of RT-PCR analysis - a simple, economical and rapid method - was appropriate for screening molecular defects in 7 of 8 X-linked CGD patients.62563

Neutrophils And Mononuclear Cells From Patients With Chronic Granulomatous Disease Release Nitric Oxide

Chronic granulomatous disease (CGD) is a group of genetic disorders characterised by recurrent severe suppurative infections due to impaired microbial killing. The principal biochemical defect is an impairment in the production of reactive oxygen intermediates by phagocytes. Nitric oxide (NO) is synthesised from the guanidino nitrogen atom(s) of L-arginine and has recently been proposed to be involved in defence mechanisms. The aim of this study was to investigate the involvement of the oxidative burst in the biosynthesis of NO by neutrophils and mononuclear cells from patients with CGD. NO synthesis was assayed by the ability of neutrophils and mononuclear cells to inhibit thrombin-induced washed platelet aggregation while superoxide anion (O2-) production was measured spectrophotometrically by the superoxide dismutase inhibitable reduction of cytochrome c. Neutrophils and mononuclear cells from patients with CGD released NO. This release was inhibited by nitro-L-arginine methyl ester but could be reversed by L-arginine. Zymosan- and PMA-induced O2- production was less than 10% as compared with health controls. These results indicate that O2- production is not essential for NO synthesis in human leucocytes.35548549

Hereditary angioedema with C1 inhibitor (C1-INH) deficit: the strength of recognition (51 cases)

Hereditary angioedema (HAE) is a rare autosomal dominant disease due to C1 esterase inhibitor deficiency (C1-INH). The disease is characterized by subcutaneous and submucosal edema in the absence of urticaria due to the accumulation of bradykinin. This descriptive study aimed to evaluate the clinical characteristics of patients with a confirmed diagnosis of HAE referred to our Outpatient Clinic between December 2009 and November 2017. Fifty-one patients (38 F, 13 M) with a mean age of 32 years (range: 7–70 y) were included. Family history of HAE was reported in 70% (36/51) of the cases; 33/46 patients became symptomatic by 18 years of age. The median time between onset of symptoms and diagnosis was 13 years (3 mo–50 y). The most frequent triggering factors for attacks were stress (74.4%), trauma (56.4%), and hormonal variations (56%). The main symptoms were subcutaneous edema in 93.5% (43/46) of patients, gastrointestinal symptoms in 84.8% (39/46), and obstruction in the upper airways in 34.8% (16/46). Hospitalization occurred in 65.2%, of whom 13.3% had to be transferred to the Intensive Care Unit. Prophylactic treatment was instituted in 87% (40/46) of patients, and 56.5% (26/46) required additional treatment to control attacks. Owing to our data collection over a period of 8 years, a significant number of patients were identified by this HAE reference center. Despite early recognition and prophylactic treatment, a high percentage of patients were hospitalized. HAE is still diagnosed late, reinforcing the need for more reference centers specialized in diagnosis and educational projects for health professionals

The use of reverse transcription-PCR for the diagnosis of X-linked chronic granulomatous disease

Chronic granulomatous disease (CGD) is an inherited disorder of the innate immune system characterized by a defective oxidative burst of phagocytes and subsequent impairment of their microbicidal activity. Mutations in one of the NADPH-oxidase components affect gene expression or function of this system, leading to the phenotype of CGD. Defects in gp91-phox lead to X-linked CGD, responsible for approximately 70% of CGD cases. Investigation of the highly heterogeneous genotype of CGD patients includes mutation analysis, Northern blot or Western blot assays according to the particular case. The aim of the present study was to use reverse transcription (RT)-PCR for the analysis of molecular defects responsible for X-linked CGD in eight Brazilian patients and to assess its potential for broader application to molecular screening in CGD. Total RNA was prepared from Epstein B virus-transformed B-lymphocytes and reverse transcribed using random hexamers. The resulting cDNA was PCR-amplified by specific and overlapping pairs of primers designed to amplify three regions of the gp91-phox gene: exons 1-5, 3-9, and 7-13. This strategy detected defective gp91-phox expression in seven patients. The RT-PCR results matched clinical history, biochemical data (nitroblue tetrazolium or superoxide release assay) and available mutation analysis in four cases. In three additional cases, RT-PCR results matched clinical history and biochemical data. In another case, RT-PCR was normal despite a clinical history compatible with CGD and defective respiratory burst. We conclude that this new application of RT-PCR analysis - a simple, economical and rapid method - was appropriate for screening molecular defects in 7 of 8 X-linked CGD patients

Guidelines In Cryptococcosis - 2008 [consenso Em Criptococose - 2008]

[No abstract available]415524544Abadi, J., Nachman, S., Kressel, A.B., Pirofski, L., Cryptococcosis in children with AIDS (1996) Clinical of Infectious Diseases15, pp. 796-800Aberg, J.A., Mundy, L.M., Powderly, W.G., Pulmonary cryptococcosis in patients without HIV (1999) Chest, 115, pp. 734-740Averbuch, D., Boekhoutt, T., Falk, R., Engelhard, D., Shapiro, M., Block, C., Polacheck, I., Fungemia in a cancer patient caused by fluconazole-resistant Cryptococcus laurentii (2002) Medical Mycology, 40, pp. 479-484Baddour, L.M., Perfect, J.R., Ostrosky-Zechener, L., Successful use of amphotericin B lipid complex in the treatment of cryptococcosis (2005) Clinical of Infectious Diseases, 40 (SUPPL. 6), pp. 409-413Behrman, R.E., Masci, J.R., Nicholas, P., Cryptococcal skeletal infections: Case report and reviews (1990) Review of Infectious Diseases, 12, pp. 181-190Bennett, J.E., Dismukes, W.E., Duma, R.J., Medoff, G., Sande, M.A., Gallis, H., Leonard, J., Alling, D.W., A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis (1979) New England Journal of Medicine, 301, pp. 126-131Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK, CDC - Centers for Disease ControlNational Institutes of HealthInfectious Diseases Society of America. Treating opportunistic infections among HIV infected adults and adolescents. MMWR -Morbidity and Mortality Weekly Report 53 (RR15): 1-112, 2004Bicanic, T., Harrison, T., Niepieklo, A., Nontobeko, D., Meintjes, G., Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazol monotherapy: The role of fluconazole resistance and immune reconstitution (2006) Clinical of Infectious Diseases, 43, pp. 1069-1073Bicanic, T., Wood, R., Meintjes Grebe, K., Brower, A., Loyse, A., Bekker, L.G., Jaffar, S., Harrison, T., High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: A randomized trial (2008) Clinical of Infectious Diseases, 47, pp. 123-130Brouwer, A.E., Rajanuwong, A., Chierakul, W., Griffin, G.E., Larsen, R.A., White, N.J., Harrison, T.S., Combination antifungal therapies for HIV-associated crytptococcal meningitis: A randomized trial (2004) Lancet, 363, pp. 1764-1767Brouwer, A.E., van Kan, H.J., Johnson, E., Rajanuwong, A., Teparrukkul, P., Wuthiekanun, V., Chierakul, W., Harrison, T.S., Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis (2007) Antimicrobial Agents Chemotherapy, 51, pp. 1038-1042Bryan, V.S., Certebral osteomyelitis due to Cryptococcus neoformans (1977) Journal of Bone and Joint Surgery, 59 A, pp. 275-278Calvo, B.M., Colombo, A.L., Fischman, O., Santiago, A., Thompson, L., Lazera, M., Telles, F., Moretti-Branchini, M.L., Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela (2001) Journal of Clinical Microbiology, 39, pp. 2348-2350Cameron, M.L., Bartlett, J.A., Waskin, H.A., Manifestation of pulmonary cryptococcosis in patients with acquired immunodeficiency syndrome (1991) Review of Infectious Diseases, 13, pp. 64-67Campbell, G.D., Primary pulmonary cryptococcosis. American Review Respiratory Diseases 94:236-243, 1996. 16. Casadevall A, Perfect JR (1998) Cryptococcus neoformans, , ASM Press, Washington DCCastro, G., Cervi, M.C., Martinez, R., Vertical transmission of Cryptococcus neoformans from a mother coinfected with human immunodeficiency virus: Case report (2006) Revista da Sociedade Brasileira de Medicina Tropical, 39, pp. 501-503Chandrasekar, P., The experience is clear (2006) International Journal Antimicrobial Agents, 27 S, pp. 31-35Chuck, S.L., Sande, M.A., Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome (1989) New England Journal of Medicine, 321, pp. 794-799Correa, M.P.S.C., Oliveira, E.C., Duarte, R.R.B.S., Pardal, P.P.O., Oliveira, F.M., Severo, L.C., Criptococose em crianças no estado do Pará, Brasil. (1999) Revista da Sociedade Brasileira de Medicina Tropical, 32, pp. 505-508Correa, M.P.S.C., Severo, L.C., Oliveira, F.M., Irion, K., Londero, A.T., The spectrum of computerized tomography (CT) findings in central nervous system (CNS) infection due to Cryptococcus neoformans var. gattii in immunocompetent children (2002) Revista do Instituto de Medicina Tropical de São Paulo, 44, pp. 283-287Dannaoui, E., Abdul, M., Arpin, M., Michel-Nguyen, A., Piens, M.A., Favel, A., Lortholary, O., Dromer, F., French Cryptococcosis Study Group. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis (2006) Antimicrobial Agents Chemotherapy, 50, pp. 2464-2470Darze, C., Lucena, R., Gomes, I., Melo, A., Características clínicas e laboratoriais de 104 casos de meningoencefalite criptocócica. (2000) Revista da Sociedade Brasileira de Medicina Tropical, 33, pp. 21-26Delgado, A.C., Taguchi, H., Mikami, Y., Myiajy, M., Villares, M.C., Moretti, M.L., Human cryptococcosis: Relationship of environmental and clinical strains of Cryptococcus neoformans var. neoformans from urban and rural areas (2005) Mycopathologia, 159, pp. 7-11Diamond, R.D., Bennett, J.B., Prognostic factors in cryptococcal meningitis. A study of 111 cases (1974) Annals of Internal Medicine, 80, pp. 176-181Dismukes, W.E., Cloud, G., Gallis, H.A., Kerkering, T.M., Medoff, G., Craven, P.C., Kaplowitz, L.G., Bowles, C.A., Treatment of cryptococcal meningitis with combination of amphotericin B and flucytosine for four as compared with six weeks (1987) New England of Medicine, 317, pp. 334-341Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O, French Cryptococcosis Study Group. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 3: e2870, 2008Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O, French Cryptococcosis Study Group. Determinants of disease presentation and outcome during cryptococcosis: The crypto A/D study. PLoS Medicine 4:e21, 2007Ellis, D.H., Pfeiffer, T.J., Ecology, life cycle, and infectious propagule of Cryptococcus neoformans (1990) Lancet, 336, pp. 923-925Ellis, D.H., Pfeiffer, T.J., Natural habitat of Cryptococcus neoformans var. gattii (1990) Journal Clinical Microbiology, 28, pp. 1642-1644Engelke, F., Moraes, V., Interações medicamentosas dos anti-retrovirais. Jornal Brasileiro de AIDS (2005), 6, pp. 189-284Ferraz, A.S., Martins, A.C.P., Becker, P.F.L., Marques, M.M.A., Suaid, H.J., Ciconelli, A.J., Criptococose disseminada pós-transplante renal. (1976) Revista do Instituto de Medicina Tropical de São Paulo, 18, pp. 120-127Fessler, R.D., Sobel, J., Guyot, L., Crane, L., Vazquez, J., Szuba, M.J., Diaz, F.G., Management of elevated intracranial pressure in patients with cryptococcal meningitis (1998) Journal of Acquired Immune Deficiency Syndrome Human Retrovirology, 17, pp. 137-142Filiú, W.F., Wanke, B., Agüena, S.M., Vilela, V.O., Macedo, R.C., Lazéra, M., Avian habitats as sources of Cryptococcus neoformans in the city of Campo Grande, Mato Grosso do Sul (Brazil) (2002) Revista da Sociedade Brasileira de Medicina Tropical, 35, pp. 591-595Franzot, S.P., Salkin, I.F., Casadevall, A., Cryptococcus neoformans var. grubii: Separate varietal status for Cryptococcus neoformans serotype A isolates (1999) Journal of Clinical Microbiology, 37, pp. 838-840Friese, G., Discher, T., Fussie, R., Schmalreck, A., Lohmeyer, J., Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease (2001) AIDS, 17, pp. 2344-2345Goldman, D.L., Khine, H., Abadi, J., Lindenberg, D.J., Pirofski, L.A., Niang, R., Casadevall, A., Serologic evidence for Cryptococcus neoformans infection in early childhood (2001) Pediatrics, 107, pp. E66Graybill, J.R., Sobel, J., Saag, M., van Der Horst, C., Powderly, W., Cloud, G., Riser, L., Dismukes, W., Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups (2000) Clinical of Infectious Diseases, 30, pp. 47-54Hospenthal DR, Bennett JE. Persistence of cryptococcomas on neuroimaging. Clinical of Infectious Diseases. 31:1303-1306, 2000. Erratum in: Clinical of Infectious Diseases 32: 175, 2001Husain, S., Wagener, M.M., Singh, N., Cryptococcus neoformans infection in organ transplant recipients: Variables influencing clinical characteristics and outcome (2001) Emerging Infectious Diseases, 7, pp. 375-381Igreja, R.P., Lazéra, M.S., Wanke, B., Galhardo, M.C., Kidd, S.E., Meyer, W., Molecular epidemiology of Cryptococcus neoformans isolates from AIDS patients of the Brazilian city, Rio de Janeiro (2004) Medical Mycology, 42, pp. 229-238Jenny-Avital, E.R., Abadi, M., Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy (2002) Clinical of Infectious Diseases, 35, pp. 128-133John, G.T., Mathew, M., Snehalatha, E., Anandi, V., Date, A., Jacob, C.K., Cryptococcus in renal allograft recipients (1994) Transplantation, 58, pp. 855-856Katsu, M., Kidd, S., Ando, A., Moretti-Branchini, M.L., Mikami, Y., Nishimura, K., Meyer, W., The internal transcribed spacers and 5.8S rRNA gene show extensive diversity among isolates of the Cryptococcus neoformans species complex (2004) FEMS Yeast Research, 4, pp. 377-388Kerkering, T.M., Duma, R.J., Shadomy, S., The evolution of pulmonary cryptococcosis. Clinical implications from a study of 41 patients with or without compromising host factors (1981) Annals of Internal Medicine, 16, pp. 611-616Kiertiburanakul, S., Sungkanuparph, S., Buabut, B., Pracharktam, R., Cryptococcuria as a manifestation of disseminated cryptococcosis and isolated urinary tract infection (2004) Japanese Journal of Infectious Diseases, 57, pp. 203-205King, C.T., Rogers, D.P., Cleary, J.D., Chapman, S.W., Antifungal therapy during pregnancy (1998) Clinical of Infectious Diseases, 27, pp. 1151-1160Kovacs, J.A., Kovacs, A.A., Polis, M., Wright, W.C., Gill, V.J., Tuazon, C.U., Gelmman, E.P., Masur, H., Cryptococcosis in the acquired immunodeficiency syndrome (1985) Annals of Internal Medicine, 103, pp. 533-538Kurokawa, C.S., Sugizaki, M.F., Peraçoli, M.T.S., (1998) Virulence factors in fungi of systemic mycoses Revista do Instituto de Medicina Tropical, 40, pp. 125-135. , São PauloKwon-Chung, K.J., Bennett, J.E., Epidemiologic differences between the two varieties of Cryptococcus neoformans (1984) American Journal of Epidemiology, 120, pp. 123-130Larsen, R.A., Leal, M.A., Chan, L.S., Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomizes trial (1990) Annals of Internal Medicine, 113, pp. 183-187Larsen, R.A., Bozzeti, S., McCutchan, J.A., Chiu, J., Leal, M.A., Richman, D.D., Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis (1989) Annals of Internal Medicine, 111, pp. 125-128Lazéra, M.S., Cavalcanti, M.A., Trilles, L., Nishikawa, M.M., Wanke, B., Cryptococcus neoformans var. gattii evidence for a natural habitat related to decaying wood in a pottery tree hollow (1998) Medical Mycology, 36, pp. 119-122Lazéra, M.S., Salmito Cavalcanti, M.A., Londero, A.T., Trilles, L., Nishikawa, M.M., Wanke, B., Possible primary ecological niche of Cryptococcus neoformans (2000) Medical Mycology, 38, pp. 379-383Leenders, A.C., Reiss, P., Portegies, P., Clezy, K., Hop, W.C., Hoy, J., Borleffs, J.C., Marie, S., Lipossomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis (1997) AIDS, 11, pp. 1463-1471Lief, M., Sarfarazi, F., Prostatic cryptococcosis in acquired immunodeficiency syndrome (1986) Urology, 28, pp. 318-319Lindenberg, A.S., Chang, M.R., Paniago, A.M., Lazéra, M.S., Moncada, P.M., Bonfim, G.F., Nogueira, S.A., Wanke, B., Clinical and epidemiological features of 123 cases of cryptococcosis in Mato Grosso do Sul, Brazil (2008) Revista do Instituto de Medicina Tropical de São Paulo, 50, pp. 75-78Lizarazo, J., Linares, M., Bedout, C., Restrepo, A., Agudelo, C.I., Castañeda, E., Grupo Colombiano para el Estudio de la Criptococosis. Results of nine years of the clinical and epidemiological survey on cryptococcosis in Colombia, 1997-2005 (2007) Biomedica, 27, pp. 94-109Lortholary, O., Management of cryptococcal meningitis in AIDS. The need for specific studies in developing countries (2007) Clinical of Infectious Diseases, 45, pp. 81-83Lortholary, O., Fontanet, A., Memain, N., Martin, A., Sitbon, K., Dromer, F., French Cryptococcosis Study Group. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France (2005) AIDS, 19, pp. 1043-1049Macsween, F.K., Bicanic, T., Brouwer, A.E., Marsh, H., Macalllan, D.C., Harrison, T.S., Lumbar drainage for control of raised cerebrospinal fluid pressure in cryptococcal meningitis: Case report and review (2005) Journal of Infection, 51, pp. 221-224Magliani, W., Conti, S., Arseni, S., Salati, A., Ravanetti, L., Maffei, D.L., Giovati, L., Polonelli, L., Antibody-mediated protective immunity in fungal infections (2005) New Microbiology, 28, pp. 299-309Malessa, R., Krams, M., Hengge, U., Weiller, C., Reinhardt, V., Volbracht, L., Rauhut, F., Brockmeyer, N.H., Elevation of intracranial pressure in acute AIDS-related cryptococcal meningitis (1994) Clinical Investigation, 72, pp. 1020-1026Mamo, G.J., Rivero, M.A., Jacobs, S.C., Cryptococal prostatic abscess associated with the acquired immune deficiency syndrome (1992) Journal of Urology, 148, pp. 889-890Mayanja-Kizza H, Oishi K, Mitarai S, Yamashita H, Nalongo K, Watanabe K, Izumi T, Ococi-Jungala , Augustine K, Mugerwa R, Nagatake T, Matsumoto K. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clinical of Infectious Diseases 26:1362-1366, 1998Menichetti, F., Fiorio, M., Tosti, A., Gatti, G., Bruna Pasticci, M., Miletich, F., Marroni, M., Pauluzzi, S., High dose fluconazole therapy for cryptococcal meningitis in patients with AIDS (1996) Clinical of Infectious Diseases, 22, pp. 838-840Meyohas, M.C., Roux, P., Bollens, D., Chouaid, C., Rozenbaum, W., Meynard, J.L., Poirot, J.L., Mayaud, C., Pulmonary cryptococcosis: Localized and disseminated infections in 27 patients with AIDS (1995) Clinical of Infectious Diseases, 21, pp. 628-633Milefchik, E., Leal, M.A., Haubrich, R., Bozzette, S.A., Tilles, J.G., Leedom, J.M., McCutchan, J.A., Larsen, R.A., Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis (2008) Medical Mycology, 46, pp. 393-395Miller Jr, W.T., Edelman, J.M., Miller, W.T., Cryptococcal pulmonary infections in patients with AIDS: Radiographic appearance (1990) Radiology, 175, pp. 725-728Programa nacional de doenças sexualmente transmissíveis (1999) Ministério da Saúde, Brasília, Ano I, 44. , Ministério da SaúdeMitchell, T.G., Perfect, J.R., Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans (1995) Clinical of Microbiology Review, 8, pp. 515-548Mitchell, D.N., Sorrell, T.C., Pancoast's syndrome due to pulmonary infection with Cryptococcus neoformans variety gattii (1992) Clinical of Infectious Diseases, 14, pp. 1142-1144Montenegro, H., Paula, C.R., Environmental isolation of Cryptococcus neoformans var. gattii and C. neoformans var. neoformans in the city of São Paulo, Brazil (2000) Medical Mycology, 38, pp. 385-390Moyses Neto, M., Muglia, V., Batista, M.S.P.N., Pisi, T.M., Saber, L.T.S., Ferraz, A.S., Infecção por fungos e transplante renal: Análise nos primeiros 500 pacientes transplantados no Hospital de Clínicas da Faculdade de Medicina de Ribeirão Preto - USP (1995) Jornal Brasileiro de Nefrologia, 17, pp. 162-170Muccioli, C., Belfort Junior, R., Lottenberg, C., Lima, J., Santos, P., Kim, M., Abreu, M.T., Neves, R., Manifestações oftalmológicas na AIDS: Avaliação de 445 pacientes em um ano. (1994) Revista da Associação Médica Brasileira, 40, pp. 155-158Mussini, C., Pezzotti, P., Miró, J.M., Martinez, E., de Quirós, J.C.L., Cinque, P., Borghi, V., Aberg, J.A., (2004) Clinical of Infectious Diseases, 38, pp. 565-571. , for the international working group on cryptococcosisNadrous, H.F., Antonios, V.S., Terrel, C.L., Ryu, J.H., Pulmonary cryptococcosis in non immunocompromised patients (2003) Chest, 124, pp. 2143-2147Newton, P.N., Thai le, H., Tip, N.Q., Short, J.M., Chierakul, W., Rajanuwong, A., Pitisuttithum, P., White, N.J., A randomized, double blind placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis (2002) Clinical of Infectious Diseases, 35, pp. 769-772Nishikawa, M.M., Lazera, M.S., Barbosa, G.G., Trilles, L., Balassiano, B.R., Macedo, R.C., Bezerra, C.C., Wanke, B., Serotyping of 467 Cryptococcus neoformans isolates from clinical and environmental sources in Brazil: Analysis of host and regional patterns (2003) Journal of Clinical Microbiology, 41, pp. 73-77Nucci, A., Maciel Júnior, J.A., Queiroz, L.S., Montenegro, M.A., Carvalho, R.B., Pseudocystic form of neurocryptococcosis in pregnancy. Case report (1999) Arquivos de Neuropsiquiatria, 57, pp. 678-682Pappas, P.G., Managing cryptococcal meningitis is about handling the pressure (2005) Clinical of Infectious Diseases, 40, pp. 480-482Pappas, P.G., Perfect, J.R., Cloud, G.A., Larsen, R.A., Pankey, G.A., Lancaster, D.J., Henderson, H., Dismukes, W.E., Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy (2001) Clinical of Infectious Diseases, 33, pp. 690-699Passoni, L.F., Wanke, B., Nishikawa, M.M., Lazéra, M.S., Cryptococcus neoformans isolated from human dwellings in Rio de Janeiro, Brazil: An analysis of the domestic environment of AIDS patients with and without cryptococcosis (1998) Medical Mycology, 36, pp. 305-311Patel, R., Paya, C.V., Infections in solid-organ transplant recipients (1997) Clinical of Microbiology Review, 10, pp. 86-124Paya, C.V., Fungal infections in solid-organ transplantation (1993) Clinical of Infectious Diseases, 16, pp. 677-688Perfect, J.R., Marr, K.A., Walsh, T.J., Greenberg, R.N., DuPont, B., Torre-Cisneros, J., Just-Nübling, G., Johnson, E., Voriconazole treatment for less-common, emerging, or refractory fungal infections (2003) Clinical Infectious Diseases, 36, pp. 1122-1131Perfect, J.R., Casadevall, A., Cryptococcosis (2002) Infection Diseases Clinical of North American, 16, pp. 837-874Pinto Jr, V.L., Galhardo, M.C.G., Lazéra, M., Wanke, B., Reis, R.S., Perez, M., Criptococose associada a aids: A importância do cultivo na urina no seu diagnostico. (2006) Revista da Sociedade Brasileira de Medicina Tropical, 39, pp. 230-232Pitisuttithurm, P., Negroni, R., Graybill, J.R., Bustamante, B., Pappas, P., Chapman, S., Hare, R.S., Hardalo, C.J., Activity of posaconazole in the treatment of central nervous system fungal infections (2005) Journal of Antimicrobial Chemotherapy, 56, pp. 745-755Powderly, W.G., Recent advances in the management of cryptococcal meningitis in patients with AIDS (1996) Clinical of Infectious Diseases, 22 (SUPPL. 2), pp. 5119-5123Quintero, E., Castañeda, E., Ruiz, A., Environmental distribution of Cryptococcus neoformans in the department of Cundinamarca-Colombia (2005) Revista Iberoamericana de Micologia, 22, pp. 93-98Revenga, F., Paricio, J.F., Merino, F.J., Nebreda, T., Ram1rez T, Mart1nez AM. Primary Cutaneous Cryptococcosis in an Immunocompetent Host: Case Report and Review of the Literature (2002) Dermatology, 204, pp. 145-149Rodrigues, M.L., Alviano, C.S., Travassos, L.R., Pathogenicity of Cryptococcus neoformans: Virulence factors and immunological mechanisms (1999) Microbes Infection, 1, pp. 293-301Rozenbaum, R., Gonçalves, A.R., Clinical epidemiological study of 171 cases of Cryptococcosis (1994) Clinical of Infectious Diseases, 18, pp. 369-380Saag, M.S., Cloud, G.A., Graybill, J.R., Sobel, J.D., Tuazon, C.U., Johnson, P.C., Fessel, W.J., Dismukes, W.E., A comparison of intraconazole versus fluconazole as maintenance therapy for AIDS associated cryptococcal meningitis (1999) Clinical of Infectious Diseases, 28, pp. 291-296Saag, M.S., Graybill, R.J., Larsen, R.A., Pappas, P.G., Perfect, J.R., Powderly, W.G., Sobel, J.D., Dismukes, W.E., Practice guidelines for the management of cryptococcal meningitis (2000) Clinical of Infectious Diseases, 30, pp. 710-718Saag, M.S., Powderly, W.G., Cloud, G.A., Robinson, P., Grieco, M.H., Sharkey, P.K., Thompson, S.E., Fisher, J.F., (1992) Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associate cryptococcal meningitis New England of Journal Medicine, 326, pp. 83-89Salyer, W.R., Salyer, D.C., Involvement of the kidney and prostata in cryptococcosis (1973) Journal of Urology, 109, pp. 695-698Seaton, R.A., Verma, N., Naraqi, S., Wembri, J.P., Warrell, D.A., Visual loss in immunocompetent patients with Cryptococcus neoformans var. gattii meningitis (1997) Transactions Royal Society Tropical Medical Hygiene, 91, pp. 44-49Seo, I.Y., Jeong, H.J., Yun, K.J., Rim, J.S., Granulomatous cryptococcal prostatitis diagnosed by transrectal biopsy (2006) International Journal of Urology, 13, pp. 638-639Sharkey, P.K., Graybill, J.R., Johnson, E.S., Hausrath, S.G., Pollard, R.B., Kolokathis, A., Mildvan, D., Gordon, D.S., Amphotericin B complex compared with Amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS (1996) Clinical of Infectious Diseases, 22, pp. 315-321Shoham, S., Cover, C., Donegan, N., Fulnecky, E., Kumar, P., Cryptococcus neoformans meningitis

Patient-centred screening for primary immunodeficiency: a multi-stage diagnostic protocol designed for non-immunologists

Efficient early identification of primary immunodeficiency disease (PID) is important for prognosis, but is not an easy task for non-immunologists. The Clinical Working Party of the European Society for Immunodeficiencies (ESID) has composed a multi-stage diagnostic protocol that is based on expert opinion, in order to increase the awareness of PID among doctors working in different fields. The protocol starts from the clinical presentation of the patient; immunological skills are not needed for its use. The multi-stage design allows cost-effective screening for PID within the large pool of potential cases in all hospitals in the early phases, while more expensive tests are reserved for definitive classification in collaboration with an immunologist at a later stage. Although many PIDs present in childhood, others may present at any age. The protocols presented here are therefore aimed at both adult physicians and paediatricians. While designed for use throughout Europe, there will be national differences which may make modification of this generic algorithm necessary